CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 10 enrolled
Drug / intervention
Neuronoff BASMATI Injectrodedevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04672096
NCT04672096N/ACompleted

Basic Assessment of Safety and Minimally Invasive Stimulation Via Injectrode

Neuronoff, Inc·interventional·Posted Dec 17, 2020·Updated Apr 19, 2024

In Brief

A clinical study evaluating Neuronoff BASMATI Injectrode for Chronic Lower Limb Pain. Completed, enrolled 10 participants across 1 site.

Detailed Summary

The objectives of this non-significant risk (NSR) study are to evaluate the safety of the short term placement of the Basmati Injectrode for up to 28 days and the efficacy of conducting electrical current to stimulate subcutaneous nerves on the explant date just prior to explant.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
CollaboratorsOhio Pain Clinic

Timeline

N/ACompletedFinished
202120222023202420252026
First PostedDec 17, 2020
Enrollment StartDec 4, 2020
Primary CompletionMay 21, 2021
TodayJul 2, 2026
Enrollment to primary: 6 monthsPosted 5.5 years ago

Interventions

Neuronoff BASMATI Injectrodedevice

The 28 day temporary placement of a Basmati Injectrode does not result in unexpected levels of inflammation or encapsulation.